Journal of Diabetes & Clinical Practice
黑料网
organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Citations : 284
Indexed In
- Google Scholar
- Publons
- ICMJE
Useful Links
Recommended Journals
Share This Page
Journal of Diabetes & Clinical Practice : Citations & Metrics Report
Articles published in Journal of Diabetes & Clinical Practice have been cited by esteemed scholars and scientists all around the world. Journal of Diabetes & Clinical Practice has got h-index 4, which means every article in Journal of Diabetes & Clinical Practice has got 4 average citations.
Following are the list of articles that have cited the articles published in Journal of Diabetes & Clinical Practice.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Total published articles |
55 | 31 | 31 | 37 | 12 | 8 | 1 | 0 |
Conference proceedings |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
11 | 24 | 23 | 28 | 16 | 13 | 14 | 20 |
| Journal total citations count | 284 |
| Journal impact factor | 0.75 |
| Journal 5 years impact factor | 0.86 |
| Journal cite score | 0.81 |
| Journal h-index | 4 |
| Journal h-index since 2019 | 4 |
 |
Lee, H., Park, S. E., & Kim, E. Y. (2021). Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of clinical medicine, 10(18), 4078. |
| | | | |
|
Jiang, L. L., Zhang, P., Liu, B. L., Yan, R. N., Ye, L., Ma, J. H., & Li, F. F. (2021). Effects of Dapagliflozin Adjunct to Insulin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized, Controlled, Open-Labeled Trial. BioMed Research International, 2021. |
| | | | |
|
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020). Age, sex, disease severity, and disease duration difference in placebo response: implications from a meta-analysis of diabetes mellitus. BMC medicine, 18(1), 1-23. |
| | | | |
|
Ceriello, A., Ofstad, A. P., Zwiener, I., Kaspers, S., George, J., & Nicolucci, A. (2020). Long-Term HbA1c Variability and Cardiovascular Death: Insights from the EMPA-REG OUTCOME Trial. |
| | | | |
|
Li, F. F., Liu, B. L., Yin, G. P., Yan, R. N., Zhang, D. F., Wu, J. D., ... & Ma, J. H. (2018). Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes. Scientific reports, 8(1), 1-7. |
| | | | |
|
Stelmaszyk, A., Weso?owska, A., Pomieczy?ska, K., Iskakova, S., Frydrychowicz, M., Dworacki, G., & Dworacka, M. (2018). The impact of dapagliflozin on glucose excursions related to early proatherogenic derangement in the aortic wall. Saudi pharmaceutical journal, 26(8), 1192-1198. |
| | | | |
|
Unnikrishnan, A. G., Saboo, B., Joshi, S., Kesavadev, J., Makkar, B. M., Agarwal, S., ... & Tiwaskar, M. (2019). Consensus Statement on Use of Ambulatory Glucose Profile in Patients with Type 2 Diabetes Mellitus Receiving Oral Antidiabetic Drugs. The Journal of the Association of Physicians of India, 67(11), 76-83. |
| | | | |
|
Milonas, D., & Tziomalos, K. (2018). Sodium-glucose cotransporter 2 inhibitors and ischemic stroke. Cardiovascular & Haematological Disorders-Drug Targets (Formerly Current Drug Targets-Cardiovascular & Hematological Disorders), 18(2), 134-138. |
| | | | |
|
Verbovoy, A. F., Pashentseva, A. V., Verbovaya, N. I., Madyanov, I. V., Sharonova, L. A., & Galkin, R. A. (2018). Modern approaches to management of cardiovascular risk factors at patients with diabetes mellitus type 2. Terapevticheskii arkhiv, 90(8), 113-117. |
| | | | |
|
Ceriello, A., Ofstad, A. P., Zwiener, I., Kaspers, S., George, J., & Nicolucci, A. (2020). Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovascular diabetology, 19(1), 1-7. |
| | | | |
|
Handelsman, Y. (2019). Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Advances in therapy, 36(10), 2567-2586. |
| | | | |
|
Araki, E., Watada, H., Uchigata, Y., Tomonaga, O., Fujii, H., Ohashi, H., ... & Langkilde, A. M. (2020). Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT?5): 52?week results from a randomized, open?label, phase III clinical trial. Diabetes, Obesity and Metabolism, 22(4), 540-548. |
| | | | |
|
Papakitsou, I., Vougiouklakis, G., Elisaf, M. S., & Filippatos, T. D. (2019). Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes. Clinical pharmacology: advances and applications, 11, 133. |
| | | | |
|
Saleem, F. (2017). Dapagliflozin: cardiovascular safety and benefits in type 2 diabetes mellitus. Cureus, 9(10). |
| | | | |
|
Palanisamy, S., Yien, E. L. H., Shi, L. W., Si, L. Y., Qi, S. H., Ling, L. S. C., ... & Chen, Y. N. (2018). Systematic review of efficacy and safety of newer antidiabetic drugs approved from 2013 to 2017 in controlling HbA1c in diabetes patients. Pharmacy, 6(3), 57. |
| | | | |
|
Li, F. F., Liu, B. L., Yan, R. N., Zhu, H. H., Zhou, P. H., Li, H. Q., ... & Ma, J. H. (2017). Features of glycemic variations in drug na脙炉ve type 2 diabetic patients with different HbA 1c values. Scientific reports, 7(1), 1-7. |
| | | | |
|
Chehregosha, H., Khamseh, M. E., Malek, M., Hosseinpanah, F., & Ismail-Beigi, F. (2019). A view beyond HbA1c: role of continuous glucose monitoring. Diabetes Therapy, 10(3), 853-863. |
| | | | |
|
Luc, K., Schramm-Luc, A., Guzik, T. J., & Mikolajczyk, T. P. (2019). Oxidative stress and inflammatory markers in prediabetes and diabetes. J. Physiol. Pharmacol, 70(6), 809-824. |
| | | | |
|
R脙楼dholm, K., Wu, J. H., Wong, M. G., Foote, C., Fulcher, G., Mahaffey, K. W., ... & Neal, B. (2018). Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes芒聙聯A systematic review. diabetes research and clinical practice, 140, 118-128. |
| | | | |
|
Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., ... & Hirano, T. (2017). Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovascular diabetology, 16(1), 1-13. |
| | | | |
